Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Has Average Price Target of $274.68

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been given a consensus recommendation of “Moderate Buy” by the twenty-one ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $274.68.

A number of equities research analysts have issued reports on AXSM shares. Morgan Stanley reduced their price objective on shares of Axsome Therapeutics from $251.00 to $247.00 and set an “equal weight” rating on the stock in a research note on Friday, September 25th. Royal Bank Of Canada restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 14th. Wells Fargo & Company upped their price target on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Needham & Company LLC lifted their price objective on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Truist Financial lifted their price target on Axsome Therapeutics from $200.00 to $285.00 and gave the company a “buy” rating in a research note on Wednesday, September 23rd.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer directly owned 10,000 shares in the company, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This trade represents a 39.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 59,664 shares of company stock worth $12,624,805 over the last quarter. 20.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AXSM. GAMMA Investing LLC lifted its holdings in shares of Axsome Therapeutics by 14.9% in the second quarter. GAMMA Investing LLC now owns 347 shares of the company’s stock worth $85,000 after buying an additional 45 shares in the last quarter. Concurrent Investment Advisors LLC boosted its position in shares of Axsome Therapeutics by 4.7% during the second quarter. Concurrent Investment Advisors LLC now owns 1,739 shares of the company’s stock worth $426,000 after acquiring an additional 78 shares during the last quarter. Assetmark Inc. increased its holdings in Axsome Therapeutics by 7.2% in the 1st quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after acquiring an additional 79 shares during the last quarter. Allworth Financial LP lifted its stake in Axsome Therapeutics by 5.7% in the 2nd quarter. Allworth Financial LP now owns 1,566 shares of the company’s stock worth $383,000 after purchasing an additional 84 shares in the last quarter. Finally, Praxis Investment Management Inc. lifted its stake in Axsome Therapeutics by 10.0% in the 1st quarter. Praxis Investment Management Inc. now owns 1,265 shares of the company’s stock worth $214,000 after purchasing an additional 115 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Axsome posted third-quarter revenue of $259.7 million, up 51.9% year over year and ahead of the approximately $249.2 million consensus estimate. Its loss narrowed to $0.25 per share, substantially better than the expected $0.63–$0.69 loss and the $0.94 loss in the prior-year quarter. Axsome Therapeutics Third-Quarter Financial Results
• Positive Sentiment: Sales increased across Axsome’s key commercial brands, supporting the company’s improving revenue base. Management also highlighted pipeline milestones expected in 2027, which could provide additional long-term growth opportunities. Axsome Q3 Sales and Pipeline Milestones
• Neutral Sentiment: The earnings beat was partly offset by continued negative profitability metrics, including a negative net margin and return on equity. Investors may therefore view the results as evidence of progress, but not yet as proof of sustainable earnings power. Axsome Q3 Key Metrics
• Negative Sentiment: AUVELITY’s ADA launch is progressing more slowly than hoped. Recent incremental growth appears to be driven more by depression prescriptions among patients under 65 than by ADA prescriptions, raising concerns about the size and pace of the new indication’s commercial opportunity. Axsome Therapeutics Sentiment Meets Reality After Q3
• Negative Sentiment: Analysts questioned the durability of the revenue beat because one-time items and improved gross-to-net adjustments contributed to reported sales, rather than solely stronger prescription volume. Piper Sandler also trimmed its price target to $235 from $238, reflecting more cautious expectations. Piper Sandler Lowers Axsome Price Target

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $136.01 on Tuesday. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of -36.27 and a beta of 0.86. The business has a 50-day moving average of $183.33 and a 200-day moving average of $198.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. Axsome Therapeutics has a fifty-two week low of $123.00 and a fifty-two week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.38. The firm had revenue of $259.69 million for the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. The business’s revenue for the quarter was up 51.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.94) earnings per share. As a group, sell-side analysts predict that Axsome Therapeutics will post -3.04 earnings per share for the current fiscal year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.